Author/Authors :
Davar, Robab Research and Clinical Center for Infertility - Yazd Reproductive Sciences Institute - Shahid Sadoughi University of Medical Sciences, Yazd, Iran , Pourmasumi, Soheila Non Communicable Diseases Research Center - Rafsanjan University of Medical Sciences, Rafsanjan, Iran , Mohammadi, Banafsheh Research and Clinical Center for Infertility - Yazd Reproductive Sciences Institute - Shahid Sadoughi University of Medical Sciences, Yazd, Iran , Mortazavi Lahijani, Maryam Research and Clinical Center for Infertility - Yazd Reproductive Sciences Institute - Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Abstract :
Background: The results of previous studies on the effect of low-dose aspirin in frozenthawed
embryo transfer (FET) cycles are limited and controversial.
Objective: To evaluate the effect of low-dose aspirin on the clinical pregnancy in the
FET cycles.
Materials and Methods: This study was performed as a randomized clinical trial from
May 2018 to February 2019; 128 women who were candidates for the FET were
randomly assigned to two groups receiving either 80 mg oral aspirin (n = 64) or no
treatment. The primary outcome was clinical pregnancy rate and secondary outcome
measures were the implantation rate, miscarriage rate, and endometrial thickness.
Results: The endometrial thickness was lower in patients who received aspirin
in comparison to the control group. There were statistically significant differences
between the two groups (p = 0.018). Chemical and clinical pregnancy rates and abortion
rate was similar in the two groups and there was no statistically significant difference.
Conclusion: The administration of aspirin in FET cycles had no positive effect on the
implantation and the chemical and clinical pregnancy rates, which is in accordance with
current Cochrane review that does not recommend aspirin administration as a routine
in assisted reproductive technology cycles.